专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

US20140013457A1 Methods of Modifying Eukaryotic Cells 审中-公开
公开(公告)号：US20140013457A1
公开(公告)日：2014-01-09
申请号：US14036518
申请日：2013-09-25
申请人： Andrew J. Murphy , George D. Yancopoulos , Margaret Karow , Lynn Macdonald , Sean Stevens
发明人： Andrew J. Murphy , George D. Yancopoulos , Margaret Karow , Lynn Macdonald , Sean Stevens
IPC分类号： C12N15/85
CPC分类号： C12P21/00 , A01K67/0275 , A01K67/0278 , A01K2207/15 , A01K2217/05 , A01K2227/105 , A01K2267/01 , C07K16/00 , C07K16/28 , C07K16/462 , C07K2317/10 , C07K2317/21 , C07K2317/24 , C07K2317/51 , C07K2317/515 , C07K2317/56 , C12N15/67 , C12N15/85 , C12N15/8509 , C12N15/902 , C12N15/907 , C12N2800/204
摘要： A method for engineering and utilizing large DNA vectors to target, via homologous recombination, and modify, in any desirable fashion, endogenous genes and chromosomal loci in eukaryotic cells. These large DNA targeting vectors for eukaryotic cells, termed LTVECs, are derived from fragments of cloned genomic DNA larger than those typically used by other approaches intended to perform homologous targeting in eukaryotic cells. Also provided is a rapid and convenient method of detecting eukaryotic cells in which the LTVEC has correctly targeted and modified the desired endogenous gene(s) or chromosomal locus (loci) as well as the use of these cells to generate organisms bearing the genetic modification.

2. 发明申请

US20120258098A1 Method of Treating Rheumatoid Arthritis with an Anti-IL-6R Antibody 有权
标题翻译：用抗IL-6R抗体治疗类风湿关节炎的方法
公开(公告)号：US20120258098A1
公开(公告)日：2012-10-11
申请号：US13462938
申请日：2012-05-03
申请人： Allen Radin , Sean Stevens , Tammy T. Huang , Joel H. Martin , Jeanette L. Fairhurst , Ashique Rafique , Eric Smith , Kevin J. Pobursky , Nicholas J. Papadopoulos , James P. Fandl , Gang Chen , Margaret Karow
发明人： Allen Radin , Sean Stevens , Tammy T. Huang , Joel H. Martin , Jeanette L. Fairhurst , Ashique Rafique , Eric Smith , Kevin J. Pobursky , Nicholas J. Papadopoulos , James P. Fandl , Gang Chen , Margaret Karow
IPC分类号： A61K39/395 , A61P29/00
CPC分类号： A61K39/3955 , A61K31/4706 , A61K31/519 , A61K31/655 , A61K38/191 , A61K39/39541 , A61K39/39558 , A61K45/06 , A61K2039/505 , C07K16/248 , C07K16/2866 , C07K2317/21 , C07K2317/56 , C07K2317/565 , C07K2317/76 , C07K2317/92 , Y10S514/885 , A61K2300/00
摘要： The present invention provides methods of preventing or treating rheumatoid arthritis using a fully human antibody or antigen-binding fragment thereof that specifically binds human interleukin-6 receptor (hIL-6R). The methods of the present invention may include administration of a second therapeutic agent, such as one or more of a non-steroidal anti-inflammatory drug (NSAID), a glucocorticoid, a disease-modifying anti-rheumatic drug (DMARD), or a TNF-alpha antagonist, T-cell blocker, anti-CD20 antibody, an IL-1, JAK or IL-17 antagonist, or any combination thereof.
摘要翻译：本发明提供使用特异性结合人白细胞介素-6受体（hIL-6R）的完全人抗体或其抗原结合片段预防或治疗类风湿性关节炎的方法。本发明的方法可以包括施用第二治疗剂，例如非甾体抗炎药（NSAID），糖皮质激素，疾病缓解性抗风湿药（DMARD）中的一种或多种，或 TNF-α拮抗剂，T细胞阻断剂，抗CD20抗体，IL-1，JAK或IL-17拮抗剂或其任何组合。

3. 发明申请

US20110311537A1 METHODS OF USING IL-1 ANTAGONISTS TO TREAT FAMILIAL MEDITERRANEAN FEVER (FMF) 审中-公开
标题翻译：使用IL-1拮抗剂治疗家族中性粒细胞（FMF）的方法
公开(公告)号：US20110311537A1
公开(公告)日：2011-12-22
申请号：US13222759
申请日：2011-08-31
申请人： SCOTT MELLIS , MARGARET KAROW , GEORGE D. YANCOPOULOS , JOANNE PAPADOPOULOS
发明人： SCOTT MELLIS , MARGARET KAROW , GEORGE D. YANCOPOULOS , JOANNE PAPADOPOULOS
IPC分类号： A61K39/395 , A61P29/00
CPC分类号： C07K14/7155 , A61K38/00 , A61K38/177 , A61K45/06 , A61K2300/00
摘要： Methods of treating, inhibiting, or ameliorating Familial Mediterranean Fever (FMF) by administering to a subject in need thereof a therapeutically effective amount of an interleukin 1 (IL-1) antagonist, are provided. The IL-1 antagonist can be an antibody or derivative thereof, which is capable of blocking or inhibiting the biological action of IL-1, thereby treating, inhibiting or ameliorating FMF. Also provided are methods of treating, inhibiting, or ameliorating FMF by administering a therapeutically effective amount of an IL-1 antagonist in combination with additional therapeutic agents, including IL-1-specific fusion proteins, TNF inhibitors, NSAIDs, steroids, and the like.
摘要翻译：提供了通过向有需要的受试者施用治疗有效量的白细胞介素1（IL-1）拮抗剂来治疗，抑制或改善家族性地中海热（FMF）的方法。 IL-1拮抗剂可以是抗体或其衍生物，其能够阻断或抑制IL-1的生物学作用，从而治疗，抑制或改善FMF。还提供了通过将治疗有效量的IL-1拮抗剂与另外的治疗剂（包括IL-1特异性融合蛋白，TNF抑制剂，NSAID，类固醇等）组合施用来治疗，抑制或改善FMF的方法。

4. 发明授权

US07608430B2 Interferon-γ antagonists and therapeutic uses thereof 有权
标题翻译：干扰素-γ拮抗剂及其治疗用途
公开(公告)号：US07608430B2
公开(公告)日：2009-10-27
申请号：US11481614
申请日：2006-07-06
申请人： Margaret Karow , Prerna Sharma
发明人： Margaret Karow , Prerna Sharma
IPC分类号： C12P21/04 , C12N15/00 , C12N5/00 , C07K14/435 , C07H21/04
CPC分类号： C07K14/715
摘要： Polypeptides and multimeric polypeptides capable of binding interferon γ which are useful therapeutically in methods of treating interferon γ-related conditions or diseases.
摘要翻译：能够结合干扰素γ的多肽和多聚体多肽，其可用于治疗干扰素γ相关病症或疾病的方法。

5. 发明授权

US07557084B2 IL-18 specific polypeptides and therapeutic uses thereof 有权
标题翻译： IL-18特异性多肽及其治疗用途
公开(公告)号：US07557084B2
公开(公告)日：2009-07-07
申请号：US11096039
申请日：2005-03-31
申请人： Margaret Karow , Prerna Sharma
发明人： Margaret Karow , Prerna Sharma
IPC分类号： A61K38/00 , C07K14/00
CPC分类号： C07K14/54 , A61K38/00 , C07K14/7155 , C07K2319/00 , C07K2319/30
摘要： Fusion polypeptides and multimeric fusion polypeptides capable of binding interleukin-18 (IL-18) with high affinity, as well as nucleic acids encoding the IL-18-specific polypeptides, which are useful therapeutically in methods of treating IL-18-related conditions or diseases. The IL-18-specific polypeptides may include components derived from IL-18 binding protein (IL-18BP), a fusion component F, an IL-18 receptor, and/or a human interleukin-1 receptor accessory protein (hIL-1RAcP).
摘要翻译：能够以高亲和力结合白细胞介素-18（IL-18）的融合多肽和多聚体融合多肽，以及编码IL-18特异性多肽的核酸，其可用于治疗IL-18相关病症或疾病 IL-18特异性多肽可以包括衍生自IL-18结合蛋白（IL-18BP），融合成分F，IL-18受体和/或人白细胞介素-1受体辅助蛋白（hIL-1RAcP）的成分，。

6. 发明申请

US20090156492A1 Methods of Using IL-1 Antagonists to Treat Autoinflammatory Disease 审中-公开
标题翻译：使用IL-1拮抗剂治疗自身炎症性疾病的方法
公开(公告)号：US20090156492A1
公开(公告)日：2009-06-18
申请号：US12259366
申请日：2008-10-28
申请人： Scott Mellis , Margaret Karow , George D. Yancopoulos , Joanne Papadopoulos
发明人： Scott Mellis , Margaret Karow , George D. Yancopoulos , Joanne Papadopoulos
IPC分类号： A61K38/17 , A61P29/00
CPC分类号： C07K14/7155 , A61K38/00 , A61K38/177 , A61K45/06 , A61K2300/00
摘要： Methods of treating, inhibiting, or ameliorating an autoinflammatory disorder, disease, or condition in a subject in need thereof, comprising administering to a subject in need a therapeutic amount of an interleukin 1 (IL-1) antagonist, wherein the autoinflammatory disorder, disease, or condition is treated, inhibited, or ameliorated. The IL-1 antagonist is an IL-1 trap, preferably comprising a sequence selected from the group consisting of SEQ ID NO: 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, or a substantially identical having at least 95% identity to the sequence shown in SEQ ID NO: 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26 and capable of binding and inhibiting IL-1. The therapeutic methods are useful for treating a human adult or child suffering from Neonatal Onset Multisystem Inflammatory Disorder (NOMID/CINCA), Muckle-Wells Syndrome (MWS), Familial Cold Autoinflammatory Syndrome (FCAS), familial mediterranean fever (FMF), or systemic onset juvenile rheumatoid arthritis (Still's Disease).
摘要翻译：在有需要的受试者中治疗，抑制或改善自身炎性疾病，疾病或病症的方法，包括向需要治疗的受试者施用治疗量的白细胞介素1（IL-1）拮抗剂，其中所述自身炎性疾病，疾病，或条件得到治疗，抑制或改善。 IL-1拮抗剂是IL-1捕获物，优选包含选自SEQ ID NO：4,6,8,10,12,14,16,18,20,22,24,26，或与SEQ ID NO：4,6,8,10,12,14,16,18,20,22,24,26中所示的序列具有至少95％的同一性，并能够结合和抑制IL- 1。治疗方法可用于治疗患有新生儿起始多系统炎症性疾病（NOMID / CINCA），Muckle-Wells综合征（MWS），家族性冷自身炎症综合征（FCAS），家族性地中海热（FMF）或全身性发病青少年类风湿关节炎（Still氏病）。

7. 发明申请

US20070087411A1 Monomeric self-associating fusion polypeptides and therapeutic uses thereof 有权
标题翻译：单体自缔合融合多肽及其治疗用途
公开(公告)号：US20070087411A1
公开(公告)日：2007-04-19
申请号：US11582929
申请日：2006-10-18
申请人： Prerna Sharma , Margaret Karow
发明人： Prerna Sharma , Margaret Karow
IPC分类号： C07K14/715 , C07H21/04 , C12P21/06
CPC分类号： C07K14/7155 , C07K2319/00
摘要： Monomeric fusion polypeptides comprising R1-M-L-M, wherein R1 is a target ligand-binding domain, M is a multimerizing component, and L is a linker capable of allowing one M component to interact with the other M component to form a self-associating monomer, optionally comprising a second target ligand-binding domain R2. Preferred target ligands include interleukin (IL)-13, IL-1, insulin-like growth factor (IGF)-1 and IGF-2.
摘要翻译：包含R1-MLM的单体融合多肽，其中R1是靶配体结合结构域，M是多聚化组分，L是能够允许一个M组分与另一M组分相互作用以形成自缔合单体的连接体，任选地包含第二靶配体结合结构域R2。优选的靶配体包括白介素（IL）-13，IL-1，胰岛素样生长因子（IGF）-1和IGF-2。

8. 发明申请

US20070020283A1 Interferon-gamma antagonists and therapeutic uses thereof 有权
标题翻译：干扰素-γ拮抗剂及其治疗用途
公开(公告)号：US20070020283A1
公开(公告)日：2007-01-25
申请号：US11481614
申请日：2006-07-06
申请人： Margaret Karow , Prerna Sharma
发明人： Margaret Karow , Prerna Sharma
IPC分类号： C12P21/04 , C07H21/04 , A61K39/00 , C07K14/715
CPC分类号： C07K14/715
摘要： Polypeptides and multimeric polypeptides capable of binding interferon γ which are useful therapeutically in methods of treating interferon γ-related conditions or diseases.
摘要翻译：能够结合干扰素γ的多肽和多聚体多肽，其可用于治疗干扰素γ相关病症或疾病的方法。

9. 发明申请

US20050204410A1 SIRT6 transgenic non-human animals and assay methods 审中-公开
标题翻译： SIRT6转基因非人动物和测定方法
公开(公告)号：US20050204410A1
公开(公告)日：2005-09-15
申请号：US11078113
申请日：2005-03-11
申请人： Margaret Karow , Raul Mostoslavsky , Frederick Alt
发明人： Margaret Karow , Raul Mostoslavsky , Frederick Alt
IPC分类号： A01K67/00 , C12N15/85 , C12Q1/68 , G01N33/53 , G01N33/567 , G01N33/573 , G01N33/68
CPC分类号： C12N15/8509 , A01K67/0276 , A01K2207/15 , A01K2217/00 , A01K2217/075 , A01K2227/105 , A01K2267/03 , A01K2267/035 , G01N33/573 , G01N2333/91142 , G01N2500/00
摘要： Assay methods for identifying agents capable of modulating SIRT6 activity or expression, as well as non-human transgenic animals useful for identifying agents capable of inhibiting aging-associated degenerative processes.
摘要翻译：用于鉴定能够调节SIRT6活性或表达的试剂的测定方法以及可用于鉴定能够抑制与老化有关的退行性过程的试剂的非人转基因动物。

10. 发明申请

US20050069987A1 Modified ciliary neurotrophic factor polypeptides with reduced antigenicity 审中-公开
标题翻译：具有降低的抗原性的修饰的睫状神经营养因子多肽
公开(公告)号：US20050069987A1
公开(公告)日：2005-03-31
申请号：US10954466
申请日：2004-09-30
申请人： Thomas Daly , Margaret Karow
发明人： Thomas Daly , Margaret Karow
IPC分类号： A61K38/00 , A61K38/18 , C07K14/475 , C12N15/12 , C12P21/02 , C07H21/04 , C07K14/525
CPC分类号： A61K38/185 , C07K14/475 , C07K2319/30
摘要： Modified human ciliary neurotrophic factor (hCNTF) molecules having reduced antigeniticy relative to non-modified hCNTF molecules are describes, as well as methods for production and methods of use, especially in the treatment of obesity and obesity-related diseases or conditions.
摘要翻译：描述了相对于未修饰的hCNTF分子具有降低的抗原性的修饰的人睫状神经营养因子（hCNTF）分子，以及生产方法和使用方法，特别是在治疗肥胖症和肥胖相关疾病或病症中。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式